Slingshot Insights | Adms Overview

ADMS Overview

Upcoming Projects (ADMS)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ADMS)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (ADMS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ADMS)

FDA PDUFA decision on Adamas; (ADMS) ADS-5102, a treatment for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, set for August 24th
Ticker: ADMS
Occurred on: Aug 24, 2017
Allergan and Adamas Announce New Expanded Indication for NAMZARIC (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
Tickers: AGN, ADMS
Occurred on: Jul 19, 2016
Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders
Ticker: ADMS
Occurred on: Jun 22, 2016
Phase 2 data of ADS-5102 for Multiple sclerosis (MS) due 2016
Ticker: ADMS
Occurred on: Jun 13, 2016
Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients
Ticker: ADMS
Occurred on: Jun 13, 2016

Strategic Initiatives (ADMS)

Don’t see a strategic initiative related to the company you care about? Create your own!